MVM Partners Amends 13D Filing for MDxHealth SA

TL;DR

MVM Partners just updated their stake in MDxHealth SA. Watch this space.

AI Summary

MVM Partners, LLC, through its affiliates MVM GP (NO.5) LP and MVM V LP, has filed an amendment (No. 3) to its Schedule 13D for MDxHealth SA, dated October 28, 2024. The filing indicates a change in beneficial ownership of the common stock of MDxHealth SA. MVM Partners, LLC is based in Boston, MA, and the filing was made under the Securities Exchange Act of 1934.

Why It Matters

This amendment signals a potential shift in control or significant stakeholding by MVM Partners in MDxHealth SA, which could influence the company's future strategic direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings like this can precede significant corporate actions or shifts in investor sentiment, warranting close monitoring.

Key Players & Entities

• MVM Partners, LLC (company) — Filing entity
• MDxHealth SA (company) — Subject company
• MVM GP (NO.5) LP (company) — Affiliated entity
• MVM V LP (company) — Affiliated entity
• Eric Bednarski (person) — Contact person at MVM Partners
• Scott Jones, Esq. (person) — Contact person at Troutman Pepper Hamilton Sanders LLP

FAQ

Key Financial Figures

• $2.00 — he Issuer at a public offering price of $2.00 per Ordinay Share. The Funds acquired a
• $300,000 — Offering for a total purchase price of $300,000. Item 4. Purpose of Transaction. It

Filing Documents

• mvm13da.htm (SC 13D/A) — 71KB
• 0002039852-24-000027.txt ( ) — 73KB

of the Schedule 13D is amended

Item 3 of the Schedule 13D is amended and supplemented as follows: On September 27, 2024, the Issuer closed a public offering (the “Offering”) of (i) 20,000,000 Ordinary Shares of the Issuer at a public offering price of $2.00 per Ordinay Share. The Funds acquired an aggregate of 150,000 Ordinary Shares in the Offering for a total purchase price of $300,000. Item 4. Purpose of Transaction.

of the Schedule 13D is amended

Item 4 of the Schedule 13D is amended and supplemented as follows: The information set forth in Items 3, 5 and 6 of this Schedule 13D is hereby incorporated by reference. The Reporting Persons intend to continuously review their investment in the Issuer, and may in the future determine (i) to acquireadditional securities of the Issuer, through open market purchases, private agreements or otherwise, (ii) to dispose of all or a portion ofthe securities of the Issuer owned by them, (iii) to undertake an extraordinary corporate transaction such as a tender offer or exchangeoffer for some or all of the shares of Common Stock not held by the Reporting Persons or a merger, acquisition, consolidation or otherbusiness combination or reorganization involving the Issuer, (iv) to engage in any hedging or similar transactions with respect tosecurities of the Issuer; or (v) to take any other available course of action. Notwithstanding anything contained herein, the ReportingPersons specifically reserve the right to change their intention with respect to any or all of such matters. In reaching any decision as totheir course of action (as well as to the specific elements thereof), the Reporting Persons currently expect that they would take intoconsideration a variety of factors, including, but not limited to, the following: the Issuer’s business and prospects other developmentsconcerning the Issuer and its businesses generally other business opportunities available to the Reporting Persons developments withrespect to the business of the Reporting Persons changes in law and government regulations general economic conditions and moneyand stock market conditions, including the market price of the securities of the Issuer and currency fluctuations. Item 5. Interest in Securities of the Issuer.

of the Schedule 13D is amended

Item 5 of the Schedule 13D is amended and supplemented as follows: The information contained in the cover pages of this Amendment is incorporated herein by reference. The percentages used in this Amendment are calculated based upon on a total of 47,288,093 outstanding shares of Common Stock of the Issuer as reported in the Issuer’s Prospectus Supplement (to Prospectus Dated December 19, 2022) filed on September 26, 2024. Each of the Reporting Persons may be deemed a member of a “group” with the other Reporting Persons for purposes of Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and may be deemed to share power to vote or direct thevote of (and share power to dispose or direct the disposition of) the securities of the Issuer owned by the other Reporting Persons. Thefiling of this Amendment shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of theExchange Act, the beneficial owners of any securities of the Issuer he or it does not directly own. Each of the Reporting Personsspecifically disclaims beneficial ownership of the securities of the Issuer reported herein that he or it does not directly own.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: October 28, 2024 MVM Partners, LLC By: /s/ Eric Bednarski Name: Eric Bednarski Title: Vice President MVM V LP By: MVM Partners, LLC, its Fund Manager By: /s/ Eric Bednarski Name: Eric Bednarski Title: Vice President MVM GP (No. 5) LP By: MVM Partners, LLC, its Fund Manager By: /s/ Eric Bednarski Name: Eric Bednarski Title: Vice President

View Full Filing

View this SC 13D/A filing on SEC EDGAR